Drug Trial Radar · NCT06906731
A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
27
Planned (sponsor's estimate)
Start
Apr 2025
Primary completion
Jun 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, multi-center, multiple doses Phase I/II study to evaluate the safety, tolerability ,pharmacokinetics and efficacy of SHR-9803 for injection in subjects with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
SHR-9803Drug
SHR-9803
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limited Toxicity(Ia)Time frame: Screening up to the end of phase Ia, an average of 6 months
- Dose Limited Toxicity (Ib)Time frame: Screening up to the end of phase Ib, an average of 1 year
- Recommended phase II dose(Ib)Time frame: Screening up to the end of phase Ib, an average of 2 years
- objective response rate(II)Time frame: Screening up to study completion, an average of 3 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Harbin Medical University cancer hospital
Harbin, Heilongjiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.